PATIENTS WITH ADVANCED SQUAMOUS NSCLC ARE IN URGENT NEED OF OPTIONS THAT MAY DELIVER TUMOR RESPONSE3

- NSCLC=non–small cell lung cancer.

- Associated with a poorer prognosis than nonsquamous3
- Tumors are often centrally located5
- Have been shown to grow twice as fast as adenocarcinoma6
- Often seen extrinsically pushing into airway structures as they grow7
- Associated with a history of smoking5
- NSCLC=non–small cell lung cancer.
- Importance of Tumor Response Rates
RESPONSE RATES ARE HELPFUL IN ASSESSING CLINICAL BENEFIT
ORR is a clinically meaningful endpoint in NSCLC trials, which can help physicians choose an appropriate treatment8Using ORR as an endpoint in oncology drug approval has a long historyResponse criteria have been used for more than 30 years9ORR=overall response rate.
TUMOR RESPONSE IS A RIGOROUS MEASUREMENT8
Spatial measurement of tumor shrinkage is a form of direct, real-time clinical assessment11Measure of the greater unidimensional diameters
RECIST Criteria10
CR=complete response
PR=partial response
SD=stable disease
PD=progressive disease
CR
Disappearance of all clinical and radiological evidence of target lesions
PR
≥30% decrease of the greater unidimensional diameters
SD
Failure to observe CR or PR, but not PD
PD
≥20% increase of the greater unidimensional diameters or presence of new lesion
Measure of the greater
unidimensional
diameters RECIST CRITERIA10Complete Response (CR)
Disappearance of all clinical and radiological evidence of target lesions
Partial Response (PR)
≥30% decrease of the greater unidimensional diameters
Stable Disease (SD)
Failure to observe CR or PR, but not PD
Progressive Disease (PD)
≥20% increase of the greater unidimensional diameters or presence of new lesion
Response assessment under RECIST guidelines is based on measurement of the longest single-dimension diameters of target lesions, which are identified at baseline.
RECIST=Response Evaluation Criteria In Solid Tumors.
YOU ARE NOW LEAVING www.abraxanepro.com
Additional Information for Readers Provided by Celgene Corporation
The clinical trial described in this article served as the
basis for the approval for ABRAXANE for Injectable Suspension.
The analyses contained in the article may differ from those in the package insert for ABRAXANE.
Please see Important Safety Information and Prescribing Information, including Boxed WARNING.
Click “OK” to proceed or “CANCEL” to return to
www.abraxanepro.com
YOU ARE NOW LEAVING www.abraxanepro.com
Additional Information for Readers Provided by Bristol Myers Squibb
The clinical trial described in this article served as the
basis for the approval for ABRAXANE for Injectable Suspension.
The analyses contained in the article may differ from those in the package insert for ABRAXANE.
Please see Important Safety Information and Prescribing Information, including Boxed WARNING.
Click “OK” to proceed or “CANCEL” to return to
www.abraxanepro.com
YOU ARE NOW LEAVING www.abraxanepro.com
Click “OK” to proceed or “CANCEL” to return to
www.abraxanepro.com
FOR HEALTHCARE PROFESSIONALS
The information contained in this section of www.abraxanepro.com is technical in nature and is intended for US healthcare professionals only.
If you are not a US healthcare professional, click “CANCEL” below to return to the patient and caregiver section of the site. Click “OK” if you are a healthcare professional.
OK CANCELFOR HEALTHCARE PROFESSIONALS
The information contained in this section of www.abraxanepro.com is technical in nature and is intended for US healthcare professionals only.
If you are not a US healthcare professional, click “CANCEL” below to return to the patient and caregiver section of the site. Click “OK” if you are a healthcare professional.
OK CANCEL